INFLATION REDUCTION ACT ALERT – NEW COST-SHARING PROTECTIONS FOR INSULIN FURNISHED UNDER THE PART B BENEFIT THROUGH A QUALIFIED ITEM OF DURABLE MEDICAL EQUIPMENT AND CERTAIN PART B DRUGS. LEARN MORE

Alerts and Announcements

Reduced Coinsurance for Certain Part B Rebatable Drugs under the Medicare Prescription Drug Inflation Rebate Program

Effective April 1, 2023 coinsurance for Part B rebatable drugs will be reduced if the drug’s price has increased at a rate faster than the rate of inflation. Please reference the link below for the updated list of rebatable drugs with reduced coinsurance amount. This list will be updated on a quarterly basis.

Please note that these changes do not apply to the Part D prescription drug coverage.

In addition, Effective July 1, 2023, insulin furnished under the Part B benefits through a qualified item of durable medical equipment (for example., a medically necessary traditional insulin pump), are subject to a beneficiary coinsurance limit for a month’s supply of such insulin (that does not exceed $35).

View the current list of Medicare Part B eligible drugs

If you have any questions, please call our Member Services Department at 1-844-969-5366 (TTY: 711). Monday – Sunday 8 a.m. – 8 p.m. October to March and Monday – Friday 8 a.m. – 8 p.m. April to September.

This section will be updated as additional information become available.




Notice – Ezri Care Artificial Tears

URGENT NOTICE TO PATIENTS WHO HAVE USED OR ARE IN POSSESSION OF EZRI CARE ARTIFICIAL TEARS LUBRICANT EYE DROPS.  DISCONTINUE ALL USE. 

The public health authorities have issued a national alert due to a possible concern with the brand Ezri Care Artificial Tears.  The public health authorities have indicated that these artificial tears may have been contaminated.  Additional information is available at the following links to the Ezri Care, CDC and FDA webpages:

Ezri Care Artificial Tears come in a blue box.  We ask that you immediately stop using or discard these artificial tears, including any that you may have received at Leon.

If you have any questions regarding this matter, please do not hesitate to contact your primary care provider.